SPRO Stock Analysis: Buy, Sell, or Hold?
SPRO - Spero Therapeutics, Inc. Common Stock
$1.17
0.00 (0.00%)
▲
5d:
-0.85%
30d:
-46.82%
90d:
-52.82%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Get Alerted When SPRO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SPRO appears deeply undervalued. Market expects -37.2% annual earnings decline despite 75% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: SPRO appears deeply undervalued. Market expects -37.2% annual earnings decline despite 75% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.76
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.20
72.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRO is currently trading at $1.17, which is considered oversold relative to its 30-day fair value range of $1.44 to $2.25. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.8) compared to its historical average (7.2). Remarkably, the market is currently pricing in an annual earnings decline of 37.2% over the next few years. This pessimistic expectation contrasts with the company's recent 75.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SPRO is in a downtrend. Immediate support is located at $1.08, while resistance sits at $1.57.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+233.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SPRO is in a downtrend. Immediate support is located at $1.08, while resistance sits at $1.57.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+233.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.44 -
$2.25
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 233.3% below Wall St target ($4.00)
Trading Range Analysis
30-Day Trading Range
$1.44 -
$2.25
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.57
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.79
Wall Street Target
$4.00
(+233.3%)
Revenue Growth (YoY)
-95.6%
Earnings Growth (YoY)
75.3%
Profit Margin
24.9%
Valuation Discount vs History
-37.2% cheaper
PE vs Historical
1.8 vs 7.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-37.2%
(market-implied from PE analysis)
1-Year Target
$1.08
(-10%)
2-Year Target
$0.97
(-19%)
3-Year Target
$0.87
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→7)
$3.52
(+193%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (4x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 4.41 | Current EPS (TTM): $0.27
Bull Case
$2.62
(+124%)
Analyst growth 100.0%, PE expands to 4.9
Base Case
$2.38
(+103%)
Market implied 100.0%, PE stable at 4.4
Bear Case
$0.81
(-31%)
Severe decline -20.0%, PE contracts to 3.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.8 to 7.2
Stabilization Target:
$4.82
(+302.0%)
PE Expansion Potential:
+302.0%
Share & Embed Analysis
Last updated: August 03, 2026 1:28 PM ET
Data refreshes hourly during market hours. Next update: 2:28 PM
Data refreshes hourly during market hours. Next update: 2:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Esther Rajavelu
SELL
87917 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
